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Ketone bodies [beta-hydroxybutyrate (bHB) and acetoacetate] are mainly produced in 
the liver during prolonged fasting or starvation. bHB is a very efficient energy substrate for 
sustaining ATP production in peripheral tissues; importantly, its consumption is preferred 
over glucose. However, the majority of malignant cells, particularly cancer cells of neuro-
ectodermal origin such as glioblastoma, are not able to use ketone bodies as a source of 
energy. Here, we report a novel observation that fenofibrate, a synthetic peroxisome pro-
liferator-activated receptor alpha (PPARa) agonist, induces bHB production in melanoma 
and glioblastoma cells, as well as in neurospheres composed of non-transformed cells. 
Unexpectedly, this effect is not dependent on PPARa activity or its expression level. The 
fenofibrate-induced ketogenesis is accompanied by growth arrest and downregulation 
of transketolase, but the NADP/NADPH and GSH/GSSG ratios remain unaffected. Our 
results reveal a new, intriguing aspect of cancer cell biology and highlight the benefits 
of fenofibrate as a supplement to both canonical and dietary (ketogenic) therapeutic 
approaches against glioblastoma.
Keywords: peroxisome proliferator-activated receptor alpha, beta-hydroxybutyrate, 3-hydroxy-3-methylglutaryl-
coa synthetase 2, transketolase
inTrODUcTiOn
Adaptation to limited nutritional resources due to a constantly changing environment is the most 
elementary challenge for organisms that are subjected to the pressures of natural selection. Metabolic 
flexibility that enables fitness and survival in cases of food shortage constitutes the basis of evolution-
ary success in terms of reproduction and preservation of offspring. Creativity in the substitution of 
glucose as a source of carbon and energy with other substrates has been the main driving force in 
prokaryotic evolution, as well as a necessity in the course of the development of multicellular organ-
isms. Warm-blooded animals, such as mammals, which have a constantly highly active metabolism, 
are particularly prone to the detrimental effects of prolonged food shortages. Development of highly 
complex structures like the human brain, which consumes about 20% of the body’s entire energy 
resources, complicated the matter even further. Therefore, tightly regulated metabolic processes 
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such as ketone body generation evolved as a rescue program 
during starvation and provided a significant survival advantage 
in environments where resources were short.
Ketone bodies, namely acetoacetate, acetone, and beta-
hydroxybutyrate (bHB) are produced in the liver during an exten-
sive fatty acid oxidation. They are the products of acetoacetyl-CoA 
and acetyl-CoA condensation. This reaction, a rate-limiting step 
of ketogenesis, leads to the formation of 3-hydroxy-3-methyl-
glutaryl-CoA (HMG-CoA) and is catalyzed by mitochondrial 
HMG-CoA synthetase (HMGCS2). Acetoacetate and bHB 
serve as highly efficient metabolic substrates and are utilized by 
peripheral tissues for energy production, at an even higher rate 
than glucose. Ketogenesis is regulated by several proteins that 
act as energy sensors, such as peroxisome proliferator-activated 
receptor alpha (PPARa), peroxisome proliferator-activated 
receptor gamma coactivator 1 alpha (PGC-1a), sirtuins, and 
AMP-dependent protein kinase (AMPK) (1–4).
Peroxisome proliferator-activated receptor alpha is a nuclear 
receptor that acts as the key transcription factor responsible for 
the mobilization of lipid stores, fatty acid oxidation, and ketogen-
esis during fasting (5, 6). PPARa is activated by free fatty acids and 
their derivatives (particularly CoA-SH esters and amides), which 
are released during fat mobilization; therefore, it acts as a meta-
bolic switch. Pharmacological agonists of PPARa, especially the 
hypolipidemic drug fenofibrate, are also able to induce fatty acid 
oxidation and ketogenesis in hepatocytes (7–9). PPARa is directly 
responsible for driving the transcription of HMGCS2 during fast-
ing or in response to a ketogenic diet (KD). Additionally, there is 
a functional peroxisome proliferator response element (PPRE) in 
the HMGCS2 promoter (−105 to −92) (10). Further regulation 
of HMGCS2 expression is unique, as it involves the binding of 
the HMGCS2 protein itself to the PPARa receptor. The resulting 
complex is then translocated into the nucleus, where it triggers 
HMGCS2 transcription (11). Further, HMGCS2 activity is also 
upregulated by post-translational modifications like deacetyla-
tion and desuccinylation on multiple lysine residues by the mito-
chondrial sirtuins Sirt3 and Sirt5, respectively, and palmitoilation 
of cysteine in the active site (12–14). Interestingly, HMGCS1, a 
cytosolic counterpart of HMGCS2 involved in steroid synthesis, 
is neither transcriptionally regulated by PPARa nor does it physi-
cally interact with this receptor (15, 16).
Principally hepatocytes and to a lesser extent epithelia from 
the kidneys and intestines are responsible for ketogenesis under 
physiological conditions, as these tissues possess the proper enzy-
matic machinery. Ketogenesis is switched on during prolonged 
fasting (over 1 day), when the glucose level in the blood is very 
low and higher levels of glucagon stimulate lipolysis and fatty acid 
flux from the adipose tissue. Glycogen from the liver and skeletal 
muscles is sufficient to sustain blood glucose levels for approxi-
mately 24 h, but after glycogen stocks are used up, reserves of fat 
are mobilized and free fatty acids released (17–19). Fatty acids are 
taken up by the liver and peripheral tissues and metabolized by 
beta-oxidation to acetyl-CoA, which is then oxidized completely 
in the TCA cycle. Lipid catabolism is carried out at a high rate, 
especially in the liver, where accumulated acetyl-CoA is trans-
formed to beta-HB and released into the blood. All extrahepatic 
tissues including cardiac and skeletal muscles absorb and oxidize 
ketone bodies readily. The hierarchy of energy metabolite con-
sumption causes ketone bodies to be used instead of glucose, 
which is spared for the brain (19). Utilization of ketone bodies 
significantly reduces the need for gluconeogenesis, the substrates 
for which are mostly provided by catabolism of protein-derived 
aminoacids (this process causes slow muscle wasting) or glycerol 
through the process of triglyceride de-esterification.
Interestingly, in contrast to other peripheral tissues, the brain 
is very limited in its capacity to utilize free fatty acids. There are 
a few reasons for this: (i) fatty acid oxidation generates large 
amounts of reduced flavin adenine dinucleotide (FADH2) that 
leads to enhanced generation of ROS by electron transport fla-
voprotein-ubiquinone oxidoreductase, which causes membrane 
peroxidation; (ii) fatty acid transport to the brain and oxidation 
within the brain is far too slow to provide enough ATP during 
periods of rapid neuronal synaptic activity and impulse genera-
tion; (iii) oxygen concentration in brain tissue is low, whereas the 
amount of oxygen needed for complete oxidation of long chain 
fatty acids is high – therefore complete oxidation could increase 
the risk of hypoxia in adjacent regions (20). Metabolism of ketone 
bodies eliminates all these drawbacks and provides a high-energy 
yield – roughly 23–26 ATP/one bHB molecule. Moreover, bHB 
is the most efficient fuel per molecule of oxygen consumed when 
compared to glucose, pyruvate, or free fatty acids, due to its ability 
to widen the redox potential gap between the respiratory complex 
I (NADH/NAD) and CoQ/CoQH2 (21–24).
Utilization of ketone bodies as a source of energy requires 
expression of enzymes involved in acetoacetate and bHB 
catabolism, such as succinyl-CoA:acetoacetate-CoA transferase 
(SCOT), also known as 3-oxoacid-CoA transferase (OXCT1) 
(EC 2.8.3.5); 3-oxoacyl-CoA thiolase, also known as acetyl-CoA 
actyltransferase (ACAT) (EC 2.3.1.9); and bHB dehydrogenase 
(EC 1.1.1.30). All of these enzymes are present in peripheral 
tissues at various levels; however, SCOT is absent in the liver to 
prevent a futile cycle of bHB synthesis and utilization (25).
In general, oncogenic transformation is associated with 
increased glucose consumption – a high rate of glycolysis, even 
in normoxia (the so-called Warburg effect), as well as avid 
consumption and metabolism of glutamine (glutaminolysis) 
(26, 27). Neoplastic cells, however, are not capable of ketone 
body consumption because the majority of cancers do not 
express the required enzymatic machinery. This phenomenon 
has been particularly well studied in brain tumor models. 
Malignant cells derived from brain tissue (neuroblastomas, 
glioblastomas multiforme, astrocytomas, and schwannomas) 
either do not express SCOT and ACAT or express these enzymes 
at very low levels, making them incapable of using ketone body 
oxidation for ATP production (25, 28). In fact, neuroblastoma 
and glioblastoma cells are only able to utilize ketone bodies 
as substrates for lipid synthesis (29–31). Cancer cells that are 
not able to metabolize bHB and acetoacetate frequently suffer 
from ketone body-induced toxicity, which has already been 
reported in neuroblastoma (30). Moreover, ketone bodies exert 
strong anti-proliferative and pro-apoptotic effects in melanoma, 
pancreatic, gastric, colon, and cervical cancer cells, as well as in 
transformed lymphoblasts (32–35). These observations provide 
a rationale for proposing a dietary restricted KD as a supportive 
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therapy against malignant glioma. Calorie/dietary restriction 
combined with a high fat/low carbohydrate (ketogenic) diet 
decreases blood glucose levels and simultaneously elevates bHB 
levels (36). This type of dietary intervention has already been 
shown to have very encouraging effects, namely inhibition of 
both tumor growth and neovascularization, as well as improved 
overall survival in patients and in various in vivo models of brain 
cancers (37–41). The Scheck team was able to achieve remark-
able results, when they applied radiation therapy along with the 
KD, they were able to achieve complete remission of malignant 
glioma (42). In addition, the ability to synthesize ketone bodies 
is frequently lost during oncogenic transformation of colonic 
epithelia, where the c-Myc oncogene transcriptionally repressed 
transcription of the HMGCS2 gene in 90% of colon carcinoma 
samples tested (43).
All these lines of evidence strongly suggest that ketogenesis is a 
process that is observed only under very particular physiological 
circumstances, which are absent in cancer cells. Furthermore, 
cancer cells neither prefer this kind of energy substrate nor flour-
ish in a ketogenic environment, which does not suit the needs 
of highly proliferating cells. However, in this paper, we present 
a novel observation that malignant cells of neuroectodermal 
origin, namely melanoma and glioblastoma cells, are capable 
of efficient synthesis and release of bHB when treated with a 
synthetic PPARa agonist, fenofibrate. Unexpectedly, the induced 
ketogenesis seems to be independent of PPARa expression level 
or its activity in these cells.
eXPeriMenTal PrOceDUres
cell culture and Treatment
Murine melanoma B16 F10 (ATCC# CRL-6475) cells were 
cultured in RPMI 1640 medium (Pan-Biotech, Germany) sup-
plemented with 10% fetal bovine serum (FBS, Pan-Biotech, 
Germany), mixture of antibiotics and antimycotics (penicillin 
50  U/ml, streptomycin 50 μg/ml, and amphotericin B 250  ng/
ml), and 2  mM glutamine (Sigma Aldrich, Germany). Human 
glioblastoma cell line LN-229 (ATCC# CRL-2611) cultures were 
maintained in DMEM (Gibco, Thermo Fischer, USA) supple-
mented with antibiotics, 10% FBS, and 2 mM glutamine. Both cell 
lines were kept at 37°C and 5% CO2 atmosphere. Primary neuro-
spheres cultures were obtained by isolating neural progenitor cells 
from whole-brains of embryonic day 17 C57BL/6 mice according 
to the previously published protocol (44). Isolated progenitor 
cells were cultured in poly-2-hydroxyethyl methacrylate (Sigma 
Aldrich, USA)-coated dishes in Neurobasal media supplemented 
with B27, Glutamax, N2, bFGF (Gibco, Thermo Fischer, USA), 
heparin (Stem Cell Technologies, USA), and 20 ng/ml EGF (Sigma 
Aldrich, USA). Neursopheres were passaged and plated on poly-
d-lysine/laminin (Sigma Aldrich, USA)-coated glass chamber 
slides. Following 4 days of differentiation, cells were treated with 
a vehicle (DMSO, Sigma Aldrich, USA) or fenofibrate (FF, Sigma 
Aldrich, USA) for 48 h, and media was collected for β-HB assay. 
FF was added to the fresh cell culture media at final concentration 
of 50 μM (Sigma Aldrich, USA, diluted from DMSO stock), and 
the PPARa inhibitor MK886 (Merck Millipore, USA) was used 
at 10 μM (45), whereas the final concentration of vehicle when 
added to the control cultures did not exceed 0.05% v/v.
Plasmids and Transfections
In order to knock down the PPARa protein level, a commercially 
available plasmid driving shRNA against PPARa was used (Santa 
Cruz Biotechnology, sc-36307-sh, USA), along with a plasmid 
producing irrelevant, control shRNA molecules (Control shRNA 
Plasmid A, Santa Cruz Biotechnology, sc-108060, USA) to gener-
ate a reference cell line. The B16 F10 cells were plated on the 60-mm 
dishes (200,000 cells per dish) transiently transfected with 1.75 μg 
of plasmids using Lipofectamine 2000 (Thermo Fisher, USA) 
reagent, and for the stable clones, the selection with puromycin 
(10 μg/ml) was applied, starting 72 h after the transfection. The cell 
lines with PPARa overexpression was prepared by the transient 
or stable transfections with pcDNA6.2/N-EmGFP-DEST vector 
(Thermo Fisher, USA) with inserted human PPARa ORF under 
the control of CMV promoter. The expression vector was prepared 
using Gateway® Cloning System (Thermo Fisher, USA). Briefly, 
PPARa ORF sequence (CR456547_1) was synthesized, optimized 
for the expression in human cells, and cloned into the pDONR221 
Entry Vector (GeneArt, Thermo Fisher, USA). Subsequently, the 
ORF insert was transferred into the pcDNA6.2/N-EmGFP-DEST 
Destination Vector via Clonase II Recombination Reaction. The 
stable clones were selected with blasticidin-S (20 μg/ml), starting 
72 h after the transfection. Transfection efficiency (in the cells co-
transfected with pDsRed2-Mito plasmid, Clontech laboratories, 
USA) and the expression of PPARa-EmGFP fusion protein were 
monitored in living cells or in fixed slides counterstained with 
DAPI in the fluorescent confocal microscope (Olympus Fluoview 
FV1000 laser scanning biological microscope).
Beta-hydroxybutyrate assay
The cells seeded in 12-well plates were treated with DMSO 
(control) or fenofibrate and/or MK886 for 48 h. The media were 
collected and centrifuged to eliminate any possible cell debris 
and then processed immediately or frozen in −80°C. The con-
centration of bHB in the cell culture media aliquots of 50 μL was 
measured using bHB colorimetric assay kit (Biovision #K632, 
USA), according to the manufacturer’s instructions. The bHB 
concentrations were calculated from the 450  nm absorbance 
recorded from the microplate reader and the standard curve 
prepared with the 1 mM bHB solution included in the kit. Every 
time the bHB production was normalized to the total cell number 
in each well. For this purpose and for assessment of cell prolif-
eration, cells were fixed and stained with crystal violet solution, 
and the cell numbers were determined by a spectrophotometric 
method, according to Kueng et al. (46).
immunoblotting
Total protein extracts were isolated from LN-229 and B16 F10 
cells using cell lysis buffer from Cell Signaling Technology, USA 
(#9803) supplemented with 1  mM PMSF, protease, and phos-
phatase inhibitor cocktails (Roche Applied Science Complete® 
and PhosphoStop®). Sample preparation and immunoblotting 
were performed according to the standard procedures described 
February 2016 | Volume 7 | Article 54
Grabacka et al. Ketogenesis in Melanoma and Glioblastoma
Frontiers in Endocrinology | www.frontiersin.org
in our previous studies (47). The following primary antibodies 
were used: anti-PPARa, rabbit polyclonal SAB2104354 (1:2,000 
dilution) Sigma Aldrich, USA; anti-PGC-1a; anti-HMGCS1; 
anti-HMGCS2 rabbit polyclonal from Santa Cruz Biotechnology 
(all in 1:1,000 dilution), USA; anti-phospho- and total ATP-
citrate lyase (ACL); anti-Acetyl-CoA synthetase (AceS1); 
anti-pyruvate kinase M2 (PKM2); and anti-transketolase (TKT) 
rabbit monoclonal from Cell Signaling Technology (USA, all in 
1:1,000 dilution). For loading control, anti-Grb2 mouse mono-
clonal antibody (1:3,000, BD Bioscience, San Jose, CA, USA) 
was used. For the signal detection anti-rabbit IgG HRP-linked 
antibodies (#7074 Cell Signaling Technology, USA), anti-mouse 
IgG (H + L), HRP conjugated antibodies (Thermo Fisher, USA), 
and a chemiluminescent peroxidase substrate SignalFire (Cell 
Signaling Technology, USA) were used. Densitometric analysis 
of immunoblots was performed using ImageJ software (NIH, 
USA).
Mitochondrial Oxygen consumption
The mitochondrial oxygen consumption rates in the immediate 
response to fenofibrate were evaluated in the B16 F10 Ctrl shRNA 
or PPARa shRNA cells using the Extracellular Flux Analyzer 
XF24 (Seahorse Biosciences, North Billerica, MA, USA), as 
previously described (48). Briefly, the day before each assay, the 
cells were plated in 24-well plates (Seahorse Biosciences, USA) 
in growth-supporting medium (25,000 cells/well). At the time 
of measurement, growth media were replaced with serum-free 
XF assay medium (Seahorse Biosciences, USA), and cartridges 
equipped with oxygen-sensitive and pH-sensitive probes 
(Seahorse Biosciences, USA) were placed above the cells. The 
oxygen consumption rate (OCR; indicative of mitochondrial 
respiration) and extracellular acidification rate (ECAR; indicative 
of glycolysis) were evaluated after injecting FF (50 μM) or vehicle 
(DMSO), followed by injections of metabolic toxins: oligomycin 
(inhibitor of ATP synthase; complex V of the Electron Transport 
Chain, ETC; 0.5 μM), carbonyl cyanide-p-trifluoromethoxyphe-
nylhydrazone (FCCP; uncoupling factor; 0.75 μM), and rotenone 
(inhibitor of mitochondrial complex I of ETC; 0.75 μM).
cell cycle and clonogenic assays
Cell cycle distribution was assessed by flow cytometry (GUAVA 
EasyCyte8HT, Merck Millipore, USA). Briefly, the aliquots of 
1 × 106 cells/ml were fixed in 70% ethanol at −20°C overnight. 
Next, cells were centrifuged at 1,600  rpm for 5  min, and the 
resulting pellets resuspended in Guava Cell Cycle reagent (Merck 
Millipore, USA). Cell cycle was evaluated using specialized soft-
ware CellCycle included in GuavaSoft 1.1.
LN-229 and wt B16 F10, PPARa shRNA, Ctrl shRNA, or 
PPARa-GFP cells were plated at the clonal density (1,000 cells 
per well in a 6-well plate). After 24 h, cells were treated with FF 
and/or MK-886. Fresh media with tested compounds were given 
every second day for the course of 12  days. Control cells were 
treated with DMSO. At the end of each experiment, cells were 
fixed and stained with the 0.25% crystal violet solution in metha-
nol, air dried, and the colonies were counted. All the conditions 
were tested in duplicates or triplicates, and the experiments were 
performed at least three times.
naDP/naDPh and gsh/gssg assays
For the calculation of the NADP/NADPH and GSH/GSSG ratios, 
cells were plated in 24-well plates (20,000/well) and treated with 
DMSO (control) or FF for 48 h. Next, cells were lysed, followed by 
the luminometric assays for NADP, NADPH, GSH and total GSH, 
and GSSG using the NADP/NADPH-Glo and GSH/GSSG-Glo 
kits (Promega, Germany), according to the attached instructions. 
The luminescence signal was recorded with the tube GloMax 
20/20 luminometer (Promega, Germany).
statistical analysis
Each experimental data points were done in triplicate, and the 
independent experiments were repeated two or three times. The 
data were analyzed using Statistica 10 StatSoft (USA) software, 
performing one-way or two-way ANOVA and post  hoc Tukey 
tests; differences between the control and experimental groups 
were considered significant for P values lower than 0.05.
resUlTs
Fenofibrate Triggers bhB Production 
regardless of PPara expression or 
activity status
Although fenofibrate is a well-known PPARa agonist used 
clinically to normalize blood lipoprotein profiles, many of 
its recently described anticancer activities do not involve the 
PPARa-driven transactivation mechanism. Our previous in vitro 
and in vivo studies conducted on various malignant cell lines of 
neurocetodermal origin demonstrated that fenofibrate inhibited 
proliferation, migration, invasion, metastatic tumor formation, 
and affected energy homeostasis, which led to metabolic catas-
trophe (48, 49). The latter effects seem to be promising and might 
aid the dietary ketogenic regimens currently being developed to 
support the conventional chemotherapies and radiotherapies 
used against gliomas. Therefore, in order to further investigate 
the strong impact that fenofibrate has on the cellular metabolism 
and to distinguish the receptor dependent and independent 
effects, we performed the experiments on neoplastic cell lines 
with varying levels of PPARa expression. The cell lines used were 
aggressive B16 F10 murine melanoma and human glioblastoma 
LN229, which both show detectable levels of endogenous PPARa 
expression (Figure 1A). PPARa knock down in B16 F10 cells was 
achieved through transcriptional silencing with specific shRNA, 
which resulted in an 85% decrease in its protein level, as estimated 
by densitometric analysis (not shown). The B16 F10 clone that 
stably overexpressed the PPARa-EmGFP fusion protein showed 
an over 12-fold increase in the level of receptor expression when 
compared to wt B16 F10 (Figure 1B). In the case of LN229 cells, 
transient transfection with a PPARa-EmGFP expression vec-
tor resulted in an enrichment of the population of cells which 
expressed high levels of nuclear PPARa-EmGFP (Figure 1C).
Treatment with fenofibrate (50 μM) induced ketogenesis in 
both B16 F10 and LN229 cells, which manifested in the production 
and release of bHB into the cell culture medium (Figure 2).The 
amount of bHB in the medium of FF-treated samples was 24-fold 
higher compared to DMSO-treated B16 F10 cells. Incubation 
FigUre 1 | Detection of the PPara protein (a) in various human 
melanoma cell lines (lu1205, WM9, a375P), human glioblastoma 
(ln229), and various clones of murine melanoma B16 F10 sublines 
expressing PPara shrna (shPPar#1 and shPPar#5, shown as 
examples) or control shrna (ctrl#2). Wt B16 F10 whole cell extract 
served as a reference. In the shPPAR#1 clone, the silencing was not 
successful, and for further experiments, B16 shPPAR#5 subline showing 
about 85% reduction of PPARa expression was chosen. The B16 F10 stable 
cell line overexpressing PPARa-EmGFP fusion protein (#5) was selected (B), 
wt B16 F10 whole cell extract is used for comparison of PPARa levels. 
Fenofibrate (FF, 50 μM, 48 h) and MK886 (10 μM, 48 h) do not affect PPARa 
protein level; DMSO was used as a control (B). The expression and 
subcellular (nuclear) localization of the fusion protein PPARa-EmGFP (green) 
is shown in B16 F10 and LN229 cells (c). Transfection with pDsRed2-Mito 
plasmid (red) indicated the transfection efficiency; nuclei are counterstained 
with DAPI (blue). Scale bar – 10 μm.
February 2016 | Volume 7 | Article 55
Grabacka et al. Ketogenesis in Melanoma and Glioblastoma
Frontiers in Endocrinology | www.frontiersin.org
with the synthetic PPARa inhibitor MK886 did not reverse 
this effect (Figure 2A). Similarly, the cells treated with shRNA 
against PPARa and control cells showed the same trend as wt B16 
F10, whereby fenofibrate efficiently induced ketogenesis, which 
resulted in a 24-fold increase in bHB production compared to 
DMSO-treated cells (Figure 2B). In B16 F10 cells transiently over-
expressing PPARa, fenofibrate was also able to trigger ketogenesis 
(Figure 2A). LN229 glioblastoma cells responded to fenofibrate 
similarly to the melanoma cells, with enhanced bHB production, 
regardless of the presence of the PPARa inhibitor MK886 or the 
level of PPARa expression (Figure 2C). Noteworthy was that the 
basal level of bHB production in DMSO-treated LN229 cells was 
about three to four times higher than in B16 F10 cells. This may 
be explained by the retained intrinsic capability of ketogenesis 
observed in normal astrocytes, which is absent in melanocytes.
Intrigued by these observations, we tested whether fenofibrate 
had a similar effect on normal cells. We used neurospheres, which 
are multicellular organoids of neurons and glia and serve as a 
simplified model of the normal brain tissue. Indeed, fenofibrate 
treatment (50 μM, 48 h) induced a statistically significant increase 
in bHB production (Figure 2D), albeit the differences between 
control and fenofibrate stimulated cultures were less pronounced 
than in case of malignant cells. Due to the difficulty in assessing the 
cell number precisely, the bHB concentrations measured in neuro-
sphere culture samples were normalized to the amount of protein. 
Thus, in order to compare the values obtained for neurospheres 
with those from melanoma and glioblastoma cells, we performed 
a recalculation. Assuming that one cell contains approximately 
240 pg of protein [in mammalian cells proteins account for 60% 
dry mass and average dry mass of a mouse embryonic fibroblast 
is 400  pg (50)], we can estimate the mean bHB production by 
control wt B16 F10 cells as 2.83  nmol/(μL*mg of protein) and 
18.28 nmol/(μL*mg of protein) in the fenofibrate-treated group; 
in LN229 glioblastoma cells, it was 3.66 and 7.82 nmol/(μL*mg 
of protein) for the control and fenofibrate groups, respectively. 
These results are considerably higher than the mean values for 
neurospheres that yielded 0.117 and 0.207 nmol/(μL*mg of pro-
tein) in control and fenofibrate-treated groups, respectively. This 
may be explained by the fact that astrocytes, which are capable of 
ketogenesis, make up only a fraction of the total cell population 
in the neurosphere. Nevertheless, it seems that the pro-ketogenic 
activity of fenofibrate is not restricted to malignant cells; rather, it 
appears that healthy cells can also respond similarly.
Ketogenesis in B16 F10 cells is 
accompanied by a Time-Dependent 
increase in the hMgcs2 Protein level
Both ketogenesis and fatty acid beta-oxidation take place in 
the mitochondria; thus, properly functioning mitochondria 
are essential for these processes. Mitochondrial HMGCS2 is 
the rate-limiting enzyme of the ketogenesis pathway (14), so 
we checked if its level increases after fenofibrate treatment. 
Indeed, HMGCS2 was upregulated in the cells treated with 
fenofibrate, regardless of the presence of MK886. Surprisingly, 
the basal HMGCS2 level was even higher in the B16 F10 cells 
with reduced PPARa expression (Figure 3A). This suggests that 
in the melanoma cells we studied, either PPARa does not play 
a role as an HMGCS2 transactivator or that the process might 
also be regulated downstream of transcription – perhaps through 
altered protein stability or turnover rate. Nevertheless, this 
observation drew our attention, and so we decided to examine 
both the ketogenic response of B16 F10 cells to fenofibrate and 
the levels of HMGCS2 following various periods of incubation 
with fenofibrate. As shown in Figure 3B, although the increase 
FigUre 2 | Beta-hydroxybutyrate (bhB) production in melanoma 
(a,B), glioblastoma cells (c) varying in the PPara level and in the 
neurosphere culture (D). FF – fenofibrate, MK886 – the PPARa inhibitor 
MK886, cell line names: PPARa shRNA – PPARa downregulation, PPARa-
EmGFP – PPARa overexpression. Statistical significance of the observed 
differences are shown as asterisks: *P < 0.05, **P < 0.001, ***P < 0.0001.
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treatment (Figure 3C). The time course of bHB production was 
similar in both B16 F10 ctrl shRNA and PPARa shRNA generat-
ing cells (Figure  3C), which suggests that although HMGCS2 
expression can be triggered quite rapidly, metabolic adaptation 
to the fenofibrate challenge takes nearly 2 days.
The increased HMGCS2 expression induced by fenofibrate was 
accompanied by the upregulation of PGC-1a levels (Figure 3A), 
which may be reflected in the stimulated mitochondrial biogen-
esis and intensification of mitochondrial metabolism. This could 
also serve as a compensatory mechanism, since our previous 
experiments showed that in LN229 cells, fenofibrate penetrated 
the mitochondria and acutely  –  albeit reversibly  –  repressed 
oxygen consumption through inhibition of the respiratory 
complex I, in a manner similar to rotenone (48). Indeed, similar 
observations were made for B16 F10 cells expressing normal or 
reduced PPARa levels (Figure 3D). Within minutes of fenofibrate 
addition to the monolayer culture, the oxygen consumption rate 
dropped significantly. Next, exposure to several metabolic toxins, 
such as oligomycin (complex V – ATP synthase inhibitor), FCCP 
(uncoupler that depolarizes mitochondrial inner membrane), 
and rotenone (irreversible complex I inhibitor) was used in order 
to obtain a respiratory profile of the cells following fenofibrate 
treatment. We demonstrated that fenofibrate-treated cells lost the 
ability to respond to oligomycin (as if ATP synthesis was already 
very weak) and barely responded to FCCP due to the lack of a 
proton gradient in the mitochondria (Figure 3D). Noteworthy, 
the reduction of PPARa levels did not significantly change the 
respiratory profiles of B16 F10 cells in either vehicle or fenofibrate 
treated cells.
HMGCS1  –  the cytoplasmic counterpart of mitochondrial 
HMGCS2  –  is involved in cholesterol biosynthesis but not 
ketogenesis. Transcription of HMGCS1 is not normally regulated 
by PPARa; thus, the observed positive effect of both fenofibrate 
and MK886 on HMGCS1 protein level was quite unexpected, 
particularly the additive stimulation of HMGCS1 expression in 
the cells treated with both fenofibrate and MK886 in wt B16 F10 
(Figure 3E).
Fenofibrate Treatment affects glucose 
catabolism and lipid synthesis Pathways
Recently published results from experiments on mice treated 
with fenofibrate revealed the complex transcriptional response in 
hepatocytes, which included: the activation of canonical PPARa 
regulated processes, such as mitochondrial and peroxisomal 
fatty acid oxidation and ketogenesis; de novo fatty acid synthesis, 
elongation, and desaturation; as well as an increase in pentose 
phosphate pathway (PPP) flux at the expense of suppressed 
glycolysis (51). Although the PPP is indispensable in all normal 
cells, including hepatocytes, it has recently gained recognition 
as being far more important to transformed cells. It not only 
provides NADPH for macromolecule biosyntheses and antioxi-
dant protection but also provides monosaccharide intermediates 
for nucleotide synthesis, both of which are the major require-
ments to carry on proliferation (52, 53). Therefore, we decided 
to inspect the level of some of the critical enzymes involved in 
the PPP and lipid biosynthesis in the B16 F10 sub-lines with 
in HMGCS2 synthesis was triggered after only a 6-h incubation 
with fenofibrate, a significant accumulation of bHB in the cell 
culture medium was not detected until 48 h after the start of the 
FigUre 3 | The expression of the key ketogenic enzyme mitochondrial hMgcs2 and Pgc-1a factor responsible for the mitochondrial biogenesis (a) 
in the cells treated with fenofibrate (FF) and the PPara inhibitor (MK886) in the B16 F10 cells expressing normal (ctrl shrna) or reduced (PPara 
shrna) levels. Fenofibrate induces a time-dependent increase of the HMGCS2 expression (B), which precedes a significant increase in the beta-hydroxybutyrate 
(bHB) production (c), independently of the PPARa level. Fenofibrate represses the oxygen consumption (D) in both normal and knocked down PPARa cells (Ctrl 
shRNA and PPARa shRNA, respectively). Fenofibrate and MK886 increase HMGCS1 expression in an additive fashion in the B16 F10 cells (e).
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different PPARa expression. We noticed an intriguing, inverse 
correlation between HMGCS2 expression, which is upregulated 
by fenofibrate, and TKT  –  the key PPP enzyme  –  linking the 
oxidative and non-oxidative branches of this pathway. Figure 4 
shows that the wt B16 F10 and Ctrl shRNA cells expressed higher 
levels of HMGCS2 after fenofibrate treatment. At the same time, 
in all cell lines fenofibrate had significantly downregulated the 
TKT level. Consequently, lower TKT levels were accompanied by 
lower levels of acetyl-CoA synthetase 1 (AceS1), phospho- and 
total ACL, and pyruvate kinase isoform M2 (PKM2) (Figure 4; 
Table 1). AceS1 is a cytoplasmic enzyme that catalyzes the con-
version of acetate into acetyl-CoA, which is necessary for lipid 
synthesis, while ACL facilitates the transport of acetyl-CoA from 
the mitochondria to the cytoplasm to provide substrates for lipid 
synthesis and gluconeogenesis. ACL phosphorylation at Ser 455 
(by PKA and Akt) enhances its enzymatic activity (54–56). PKM2 
is an isoform of suboptimal affinity for the substrate, so the reac-
tion rate is not as high as with other pyruvate kinase isoforms. 
PKM2 is highly expressed in embryonic and cancer cells, where 
it is believed to help them to spare glycolytic intermediates for 
the synthesis of macromolecules, such as lipids. Taken together, 
it appears that intensive ketogenesis, induced by fenofibrate, 
is associated with a downregulation of fatty acid biosynthetic 
pathways.
Ketogenesis is accompanied by an arrest 
in Proliferation
Similarly to our previously reported results (49, 57), fenofibrate 
induced growth arrest and blocked proliferation of both B16 
F10 and LN229 cells. Fenofibrate increased the percentage of 
quiescent cells (G0/G1 phase) while concomitantly reducing the 
fraction of cells in S and G2/M phases (Figure 5A). Moreover, 
FigUre 4 | hMgcs2 expression is inversely correlated with the level 
of enzymes involved in pentose phosphate pathway, transketolase 
(TKT) and the glycolytic enzyme pyruvate kinase PKM2, as well as 
lipogenic enzymes acetyl-coa synthetase (aces1) and aTP-citrate 
lyase (total and phospho-ser455). Fenofibrate reduces the ATP-citrate 
lyase phospho- and total protein levels. Grb2 detection is a loading control. 
The relative changes (comparing to the signal from the DMSO-treated wt B16 
F10 cells) of the protein band intensities in each condition (Table 1).
TaBle 1 | Densitometry of the immunoblotting results from Figure 4: protein band densitometry (band intensity normalized to grb2 signal and wt 
B16 F10 DMsO, mean±sD).
cell line Treatment Transketolase  
(TKT) (n=3)
Pyruvate kinase 
(PKM2) (n=5)
acetyl-coa synthetase 
(aces1) (n=3)
Phospho-aTP-citrate  
lyase (n=3)
aTP-citrate lyase 
(n=3)
wt B16 F10 DMSO 1.00 1.00 1.00 1.00 1.00
FF 50 μM 0.20 ± 0.078 0.74 ± 0.286 0.90 ± 0.119 0.54 ± 0.208 0.76 ± 0.296
MK886 10 μM 0.93 ± 0.361 1.06 ± 0.412 0.94 ± 0.131 0.98 ± 0.381 0,99 ± 0.383
FF + MK886 0.16 ± 0.063 0.78 ± 0.302 0.88 ± 0.226 0.84 ± 0.327 0.73 ± 0.082
Ctrl shRNA DMSO 1.18 ± 0.420 0.96 ± 0.371 0.79 ± 0.458 0.62 ± 0.239 1.00 ± 0.390
FF 50 μM 0.08 ± 0.033 0.69 ± 0.267 1.01 ± 0.102 0.55 ± 0.214 0.55 ± 0.212
PPARa 
shRNA
DMSO 0.43 ± 0.167 0.48 ± 0.184 0.92 ± 0.049 0.76 ± 0.293 0.42 ± 0.164
FF 50 μM 0.18 ± 0.068 0.62 ± 0.240 1.01 ± 0.344 0.65 ± 0.252 0.42 ± 0.164
PPARa-
EmGFP
DMSO 0.88 ± 0.343 0.45 ± 0.175 0.93 ± 0.086 0.72 ± 0.281 0.51 ± 0.197
FF 50 μM 0.22 ± 0.084 0.38 ± 0.148 0.59 ± 0.113 0.34 ± 0.134 0.52 ± 0.201
February 2016 | Volume 7 | Article 58
Grabacka et al. Ketogenesis in Melanoma and Glioblastoma
Frontiers in Endocrinology | www.frontiersin.org
FF treatment also blocked colony formation (Figures 5B–F) in a 
PPARa-independent manner, since the PPARa inhibitor MK886 
was not able to reverse this effect (Figures 5B–D). Nucleotide and 
lipid biosynthesis are indispensable for sustaining proliferation 
and both require a supply of NADPH. Downregulation of TKT 
may negatively influence the course of PPP and consequently 
NADPH generation. We suspected that such a decrease in the 
NADPH/NADP ratio might be responsible for the slowdown in 
macromolecule synthesis and impaired antioxidant protection, 
which largely relies on both GSH levels and NADPH-dependent 
glutathione peroxidase activity. A shortage of macromolecules 
for membrane and DNA synthesis as well as reduced protection 
from oxidative stress are both sufficient to induce growth arrest; 
thus, we decided to estimate changes in NADP/NADPH and 
GSH/GSSG ratios in B16 F10 cells treated with fenofibrate. We 
did not detect any statistically significant changes in the NADP/
NADPH ratio (Figure 6A). In the case of glutathione, fenofibrate 
indeed moderately decreased the GHS/GSSG ratio in cells with 
normal PPARa levels (ctrl shRNA); however, the changes were 
insignificant (Figure 6B). In cells with PPARa depletion or over-
expression, the effect of fenofibrate was hardly visible. Altogether, 
this suggests that the oxidative branch of the PPP, which directly 
produces NADPH or NADPH-generating malic enzyme, is active 
enough to maintain NADPH/NADP homeostasis, despite the 
fenofibrate-driven reduction of TKT levels. The cells also cope 
quite well and maintain a fairly constant GSH/GSSG ratio, which 
suggests that an oxidative stress is not the reason for the inhibi-
tion of proliferation.
DiscUssiOn
Production and release of ketone bodies has never been observed 
in any transformed cells. It was believed that not only particular 
types of normal cells and primarily hepatocytes but also kidney 
and intestinal epithelial cells, as well as astrocytes, were able to 
carry out ketogenesis in particular physiological conditions, such 
as prolonged fasting, a KD, or a calorie restricted ketogenic diet 
(CRKD).
In this study, we show that cancer cells of neuroepithelial 
origin, namely melanoma and glioblastoma, can abundantly 
produce bHB when treated with fenofibrate, a potent PPARa 
pharmacological agonist and a hypolipidemic drug. Fenofibrate 
promotes ketogenesis not only in the malignant cells but also 
in neurospheres composed of neurons and glia (Figure  2D). 
Although it is generally established that PPARa is the main 
transcription factor responsible for the induction of fatty acid 
catabolism and subsequent ketogenesis, in our experimental 
setting, the fenofibrate-induced bHB production seemed to be 
a PPARa-independent phenomenon. Neither the knock down of 
PPARa protein level nor its overexpression affected the ability of 
FigUre 5 | Fenofibrate induces cell cycle arrest in the g0/g1 phase in a dose-dependent manner in B16 F10 cells (a). The graphs (B–F) present the 
changes in cell numbers in melanoma (wt B16 F10, Ctrl shRNA, PPARa shRNA, and PPARa-EmGFP) and glioblastoma (LN229) cells after the 48 h incubation with 
fenofibrate (FF, 50 μM), the PPARa inhibitor MK886 (MK, 10 μM), or both. DMSO was used as a control. The photos under each graph show the representative 
dishes from the clonogenic assays, stained with crystal violet.
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FigUre 6 | Fenofibrate does not alter the naDP to naDPh (a) nor the 
gsh to gssg (B) ratios in B16 F10 cells, regardless of PPara level 
(PPara control level – ctrl shrna, PPraa knock down – PPara 
shrna, PPara overexpression – PPara-emgFP).
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cells to produce and release bHB. Similarily, the effect of fenofi-
brate was not reversed when the PPARa transcriptional activity 
was blocked by MK886. Ketogenesis activated by fenofibrate 
started after only 6  h of treatment as manifested by HMGCS2 
upregulation, but the cells needed about 48 h to fully adapt to 
this process (Figure 3B). Interestingly, both fenofibrate and the 
PPARa inhibitor MK886 also upregulated the levels of cytoplas-
mic HMGCS1, an enzyme involved in cholesterol synthesis.
The capacity of cancer cells to produce ketone bodies described 
here is quite different from previous reports, including series of 
papers (58–60) by the Lisanti group and coworkers regarding the 
possibility of ketogenesis in stromal fibroblasts surrounding breast 
cancer lesions. In those papers, the authors showed that cancer 
cells actively contributed to the stromal fibroblasts’ metabolic 
reprograming and took advantage of the subsequent ketone body 
consumption for energy generation. This is a special property of 
epithelia-derived tumors, such as breast carcinomas, since other 
cancer types do not express the proper enzymatic machinery for 
ketone body utilization as a source of energy (25, 28, 34). More 
often, cancers such as neuroblastomas or astrocytomas do absorb 
ketone bodies, but they use them for lipid synthesis rather than 
energy production (61–63). We cannot exclude the possibility 
that the cells in our study reabsorb and utilize some bHB, but 
neither B16 F10 melanoma nor LN229 glioblastoma employ it to 
obtain a growth advantage.
Recently, it has emerged that ketone bodies play much more 
complex roles than merely providing energetic substrates or 
metabolic intermediates, as they can also act as signaling mol-
ecules (64). On one hand, absorption and utilization of bHB 
decreases the intracellular NAD to NADH ratio and therefore 
affects the activity of sirtuins, but on the other hand, bHB is an 
inhibitor of class I histone deacetylases (HDAC 1, 2, 3, 8) and 
class IIa histone deacetylases (HDAC 4, 5, 7, 9) that bind zinc 
atoms at the active site (24, 64). The suppression of HDAC activity 
leads to various epigenetic modulations associated with global 
histone hyperacetylation. In this way, bHB exerts pleiotropic 
effects. For example, it induces the stress response gene FOXO3A, 
which is a tumor suppressor gene responsible for cell cycle arrest, 
reactive oxygen species detoxification, and apoptosis in various 
stressogenic conditions (65, 66). Indeed, in our previous stud-
ies, we observed the accumulation of FOXO3A in the nucleus 
and enhanced transcriptional activity of this protein in LN229 
glioblastoma cells treated with fenofibrate. We also noted that 
FOXO3A was responsible for triggering apoptosis following 
prolonged exposure to fenofibrate (49). In light of our results, it is 
possible that bHB released by LN229 cells treated with fenofibrate 
can activate an autocrine loop and drive FOXO3A translocation 
and activation.
Melanoma and glioblastoma cells rarely derive a significant 
amount of energy from fatty acid beta-oxidation, although 
some advanced melanoma cells have been shown to upregulate 
enzymes involved in fatty acid catabolism and OXPHOS (67). 
In this study, however, we did not detect changes in the protein 
levels of enzymes involved in mitochondrial and peroxisomal 
fatty acid oxidation, namely acyl-CoA dehydrogenase and acyl-
CoA oxidase, respectively (our unpublished data). Moreover, 
fenofibrate severely reduced mitochondrial oxygen consumption 
(Figure  3D), which suggests possibility that the peroxisomal 
beta-oxidation was actually responsible for the generation 
of acetyl-CoA needed for ketone bodies synthesis. The non-
mitochondrial oxygen consumption level (the level that was 
retained after rotenone injection, Figure  3D) was not affected 
by fenofibrate treatment. This would suggest that fenofibrate 
forces the cancer cells to oxidize fatty acids in peroxisomes, 
which does not result in ATP production (ATP is not generated 
in peroxisomes). This may lead to the severe energetic stress 
that we have observed previously (48, 49). This energetic stress 
certainly contributes to the slowdown of proliferation and cell 
growth arrest as demonstrated by cell cycle analysis and colony 
formation assays (Figure 5).
Puzzled by the cellular response to fenofibrate, we tried to 
determine which other metabolic pathways are altered following 
treatment. We found that there was a strong downregulation of 
TKT, the main enzyme of the non-oxidative branch of the PPP. 
The non-oxidative branch of the PPP is responsible for monosac-
charide backbone conversions leading to the synthesis of ribose 
precursors, but is not a source of NADPH. Indeed, the NADP to 
NADPH ratio in the cells treated with fenofibrate remained unaf-
fected (Figure 6A). Importantly, the non-oxidative PPP branch 
is indispensable for ribose synthesis in tumor cells, where it 
provides between 70 and 85% of ribose stocks (52, 68). Therefore, 
the downregulation of TKT by fenofibrate and subsequent limita-
tion of ribose flux may be another factor contributing to the cell 
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growth arrest seen following fenofibrate treatment. The PPP is 
active in most tissues and almost all cells need sugar phosphate 
intermediates to produce not only nucleotides for nucleic acid 
synthesis but also crucial nucleotide derivatives, such as NAD(P), 
FAD, ATP, and CoA-SH.
Melanoma cells are able to sustain NADPH levels and maintain 
a fairly constant NADP/NADPH ratio, most likely through other 
NADPH reducing reactions either by NADP-dependent malic 
enzymes or nicotinamide nucleotide transhydrogenase (NNT). 
Malic enzyme catalyzes the oxidative decarboxylation of malate 
to pyruvate with a concomitant reduction of NADP to NADPH. 
Malic enzyme’s isoforms ME2 and ME3 reside in mitochondria 
whereas ME1 is cytosolic, and all of them are frequently over-
expressed in tumor tissues of diverse origin (69–73). Recently, a 
reciprocally opposite regulation between p53 and ME1 and ME2 
has been reported, showing that p53 knock out increases malic 
enzymes expression and that this gives the tumor cells a growth 
advantage, facilitating glutaminolytic flux and lipogenesis (74). 
Transhydrogenase NNT is a mitochondrial inner membrane 
protein that functions as a proton pump and simultaneously 
transfers protons and electrons from one type of reducing 
equivalent (NADH) to another (NADPH) (75). This enzyme 
has also garnered interest in the context of cancer metabolism, 
because it replenishes mitochondrial NADPH stocks required 
for isocitrate dehydrogenase-driven reductive carboxylation of 
a-ketoglutarate to isocitrate, which is employed by cancer cells to 
enhance lipogenesis (76).
In conclusion, it is quite surprising that fenofibrate is able to 
reprogram melanoma and glioblastoma metabolic pathways in 
such a way that they suffer from an energy deficit but are still 
forced to produce ketone bodies. This finding is important 
because, as far as we are aware, ketogenesis in cancer cells has not 
been described before and the underlying mechanism still waits 
to be revealed. The ketone bodies released by glioblastoma cells 
could serve not only as a fuel but also as a cytoprotective signal-
ing molecule for neurons in the microenvironment surrounding 
the tumor tissue. The inability of neuroectodermal cancers to 
metabolize ketone bodies for their own benefit was long ago 
put forth as the rationale for the implementation of a KD as a 
therapeutic option for brain tumors, and it was later supported 
with experimental and clinical evidence (41, 77–80). Our results 
seem to further support this notion, as well as suggest some 
pharmacological agents, such as fenofibrate, as a supplement for 
such dietary therapeutic regimens.
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